Literature DB >> 8980234

Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.

T R Gamble1, F F Vajdos, S Yoo, D K Worthylake, M Houseweart, W I Sundquist, C P Hill.   

Abstract

The HIV-1 capsid protein forms the conical core structure at the center of the mature virion. Capsid also binds the human peptidyl prolyl isomerase, cyclophilin A, thereby packaging the enzyme into the virion. Cyclophilin A subsequently performs an essential function in HIV-1 replication, possibly helping to disassemble the capsid core upon infection. We report the 2.36 A crystal structure of the N-terminal domain of HIV-1 capsid (residues 1-151) in complex with human cyclophilin A. A single exposed capsid loop (residues 85-93) binds in the enzyme's active site, and Pro-90 adopts an unprecedented trans conformation. The structure suggests how cyclophilin A can act as a sequence-specific binding protein and a nonspecific prolyl isomerase. In the crystal lattice, capsid molecules assemble into continuous planar strips. Side by side association of these strips may allow capsid to form the surface of the viral core. Cyclophilin A could then function by weakening the association between capsid strips, thereby promoting disassembly of the viral core.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980234     DOI: 10.1016/s0092-8674(00)81823-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  346 in total

1.  Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.

Authors:  C Liang; L Rong; Y Quan; M Laughrea; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Authors:  M Srivastava; M Cartas; T A Rizvi; S P Singh; D Serio; V S Kalyanaraman; H B Pollard; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab.

Authors:  C Berthet-Colominas; S Monaco; A Novelli; G Sibaï; F Mallet; S Cusack
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

4.  Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions.

Authors:  J B Bowzard; J W Wills; R C Craven
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Analysis of Mason-Pfizer monkey virus Gag particles by scanning transmission electron microscopy.

Authors:  S D Parker; J S Wall; E Hunter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Molecular organization of Mason-Pfizer monkey virus capsids assembled from Gag polyprotein in Escherichia coli.

Authors:  Milan V Nermut; Patrick Bron; Daniel Thomas; Michaela Rumlova; Tomas Ruml; Eric Hunter
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes.

Authors:  L S Ehrlich; T Liu; S Scarlata; B Chu; C A Carter
Journal:  Biophys J       Date:  2001-07       Impact factor: 4.033

9.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.